Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

Signorovitch, James; Wu, Eric Q.; Betts, Keith A.; Parikh, Kejal; Kantor, Evan; Guo, Amy; Bollu, Vamsi; Williams, Denise; Wei, Liuya; DeAngelo, Daniel J.

doi:10.1185/03007995.2011.576238

Cited by 49 publications

(39 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…82 Another paper also provided indirect comparison analysis of dasatinib and nilotinib. 83 Additional data were also retrieved from the industry submissions of Bristol-Myers Squibb (BMS, 2011, unpublished; dasatinib) and Novartis (2011, unpublished;nilotinib). 84,85 The details of studies retrieved as full papers and subsequently excluded, along with the reasons for their exclusion, are detailed in Appendix 5.…”

Section: Identification Of Evidencementioning

confidence: 99%

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Pavey

Hoyle²,

Ciani³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTADasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills ...

show abstract

Section: Identification Of Evidencementioning

confidence: 99%

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Pavey

Hoyle²,

Ciani³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…However, like all other indirect comparison methods, matching-adjusted indirect comparisons are limited in that they cannot account for confounding resulting from unobservable cross-trial differences [21]. This method has been applied successfully in multiple diseases [22][23][24][25]. In the absence of randomized controlled trials involving direct treatment comparisons, indirect treatment comparisons can also be used by healthcare policy makers and payers to assess the decision to prescribe or cover a treatment [26].…”

mentioning

confidence: 99%

Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison

et al. 2017

View full text Add to dashboard Cite

Aim: Using matching-adjusted indirect comparison, we compared efficacy outcomes in patients with relapsing-remitting multiple sclerosis treated with delayed-release dimethyl fumarate (DMF) or glatiramer acetate (GA). Materials & methods: An indirect comparison of DMF (patient-level data) and GA (aggregate data) was conducted, with average baseline characteristics of DMF patients weighted to match those for GA patients. Direct comparison of DMF and GA was conducted in CONFIRM. Final results pooled the indirect and direct comparisons using meta-analysis. Results: After matching, baseline characteristics were balanced between DMF and GA patients. Compared with GA, efficacy was significantly in favor of DMF as measured by annualized relapse rate (rate ratio: 0.76; 95% CI: 0.57-1.00; p = 0.0474) and 12-week confirmed disability progression (risk ratio: 0.59; 95% CI: 0.46-0.76; p < 0.0001). Conclusion: DMF demonstrated superior clinical efficacy versus GA.

show abstract

“…Indirect comparisons with IPD can resolve differences in outcome definitions: nilotinib versus dasatinib in newly diagnosed chronic myelogenous leukemia chronic phase [36] Nilotinib and dasatinib, both recently approved by the Food and Drug Administration for the treatment of newly diagnosed chronic myelogenous leukemia (CML) In the chronic phase, have superior efficacy compared with the previous standard of care, imatinib [37,38]. There are only two published trials of nilotinib or dasatinib for CML chronic phase (ENESTnd and DASISION), each compared with imatinib [39,40].…”

Section: Example Applicationsmentioning

confidence: 99%

“…Selected baseline characteristics and outcomes before and after matching-nilotinib vs. dasatinib in the treatment newly diagnosed CML-CP patients36 .…”

mentioning

confidence: 99%

Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

Abstract: Nilotinib was associated with significantly higher rates of MMR and overall survival compared with dasatinib by month 12 in the treatment of newly diagnosed CML-CP.

Cited by 49 publications

References 17 publications

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison

Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research

Contact Info

Product

Resources

About